Muna Abuerreish, MD
Infectious Disease · Kansas City, MONPI 1790870020
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.3% of the total across 179 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,129 and has fallen 95.7% since, to $48 in 2023.
Across 179 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$549
- Johnson & Johnson$510
- Merck$476
- Gilead$376
- AbbVie$191
- Melinta Therapeutics, LLC$185
- plus $865 from 14 others
What the payments were for
- Speaking & faculty fees$1234%
- Food & beverage$2,84790%
- Education$1816%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 35 | $549 |
| Johnson & Johnson | 31 | $510 |
| Merck | 30 | $476 |
| Gilead | 23 | $376 |
| AbbVie(2 entities) | 10 | $191 |
| Melinta Therapeutics, LLC | 11 | $185 |
| Napo Pharmaceuticals Inc | 8 | $158 |
| Astellas Pharma US Inc | 3 | $138 |
| Insmed, Inc. | 6 | $121 |
| La Jolla Pharmaceutical Company | 6 | $107 |
| Theratechnologies Inc. | 5 | $82 |
| Janssen Products, LP | 1 | $70 |
| Mylan Institutional Inc. | 2 | $47 |
| Nabriva Therapeutics, PLC | 2 | $34 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $23 |
| Mayne Pharma Commercial LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Shionogi Inc | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$3,151 in reported general payments places this provider in the 75th percentile of 177 infectious disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Kansas City
- Joseph BrewerKansas City$7K
- Paul JostKansas City$6K
- Arundhati DesaiKansas City$3K
- David McKinseyKansas City$796
- Robert BelsheSaint Louis$382K
- Erik DubberkeSaint Louis$144K
- Rupa PatelSaint Louis$96K
- Michael DiamondSaint Louis$44K
- Nirmol PhilipChesterfield$31K
- Andrej SpecSaint Louis$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.